Introduction {#s1}
============

Drugs are important agents for combating the ailments. Drugs are mainly divided into hydrophilic and lipophilic types according to solubility. Hydrophilic drugs, in general, have difficulties entering cells through passive diffusion because cell membranes are composed mainly of lipid bilayers ([@B111]). However, lipophilic drugs are often difficult to dissolve in water and have unsatisfactory bioavailability ([@B6]). Recently, gene drugs including DNA drugs, RNA drugs have shown promise in treating mutant gene-associated diseases ([@B49]). Different from chemical drugs, these gene drugs are much larger and have difficulties entering cells. Meanwhile, gene drugs are easily degraded by nucleases in blood stream or cells.

To address the shortcomings of chemical and gene drugs in clinical practices, drug-delivery carriers are used to encapsulate drugs to improve the water solubility of lipophilic drugs, enhance the penetration of hydrophilic drugs into cells, and decrease the side-effect of drugs. For example, the nanoliposomal encapsulation improve the water solubility and bioavailability of hydrophobic polyphenol curcumin (diferuloylmethane) and enhance anticancer activity of curcumin against breast cancer ([@B29]). Additionally, delivery systems can also protect gene drugs from degradation by extracellular and intracellular enzymes, and promote therapeutic outcome ([@B12]).

Advanced drug delivery systems (DDS) require a demand of dosage, spatial, and temporal control strategy ([@B68]). Several studies have shown that microspheres and nanoparticles can protect drugs or genes and further improve therapeutic outcomes ([@B82]; [@B2]; [@B34]; [@B133]). However, the uncontrolled release of drugs and genes at the disease site is the main limitation of microspheres and nanoparticles.

Since 1978, stimuli-responsive delivery systems have been widely investigated to control release of drugs and genes in targeted sites ([@B131]). Recently, the commonly used stimuli include microenvironment pH and enzymes in target tissues, as well as external stimuli such as photons, electromagnetic, and ultrasound waves. It supplies new perspective for the study of control release of drugs and genes in delivery system. Ultrasound wave is a promising physical stimulus for drug/gene delivery because of its safety, low cost, and portability of ultrasound instrument ([@B22]).

Ultrasound, including low frequency (\<100 kHz) and high frequency (\>100 kHz and MHz range) ultrasound ([@B45]; [@B75]), as one of the most commonly used physical factors has been widely employed in the disease diagnosis and therapy ([@B122]). Since the mid-1990s, it has been demonstrated that ultrasound can enhance the permeability of agents into living cells ([@B62]). Ultrasound sonication improves the delivery efficiency of drugs/genes mainly through thermal and non-thermal effect ([@B39]; [@B61]; [@B17]; [@B30]; [@B109]; [@B23]; [@B65]). The thermal effects are produced from the absorption of acoustic energy in biological tissues. While the non-thermal effects are mainly generated from ultrasound pressure, acoustic streaming, shockwaves, liquid microjet, and ultrasound-induced oscillation or cavitation ([@B74]; [@B39]; [@B73]). In particular, in the presence of cavitation nuclei, a type of particles which can lower acoustic intensity to induce cavitation, ultrasound shows higher delivery efficiency ([@B79]; [@B120]; [@B87]; [@B73]).

In view of the advantages of cavitation nuclei in ultrasound stimuli, microbubbles as cavitation nuclei have been used widely in ultrasound-mediated drug/gene delivery ([@B37]; [@B129]; [@B86]; [@B118]; [@B140]). The commonly used microbubbles have gaseous cores and outer shells composed of phospholipids, polymers or proteins. The size of microbubbles (about 1--10 μm) enables them to circulate with red blood cells ([@B44]; [@B98]; [@B81]). Microbubbles, as proven ultrasound-responsive materials, have been applied in drug delivery in clinical trials ([**Table 1**](#T1){ref-type="table"}) ([@B43]; [@B18]; [@B31]). These clinical trials confirmed the controllability of delivering the cargo like drugs and gene materials with ultrasonic switch and visualization of treatment. Most noteworthy, many preclinical studies were also under study. [@B54] used doxorubicin-loaded microbubbles in combination with ultrasound (1 MHz) to facilitate the entering of doxorubicin into osteosarcoma cells and exhibited 3.7-fold inhibition of cancer growth compared to doxrubicin-loaded microbubbles without sonication, and simultaneously in combination with contrast-enhanced ultrasound imaging doxorubicin-loaded microbubbles were used to monitor the perfusion and volume of cancer. [@B60] delivered miR-29b-3p to enhance fracture healing using ultrasound microbubbles system. Even in articular cartilage to which it is difficult to deliver drugs, ultrasound-responsive microbubbles can also improve the drug delivery efficiency ([@B85]). However, microbubbles have a short circulation time in blood because their sizes restrict their passage through the barrier between blood vessels and targeted tissues. For example, tumor tissues permit only smaller particles (\<1 μm) to enter their interior ([@B140]). In particular, nanoparticles of size 1--100 nm can have high accumulation in tumor tissues *via* the enhanced permeability and retention (EPR) effect ([@B71]; [@B7]).

###### 

Clinical trials of materials assisting drug delivery under sonication \[the datasets for this table can be found in the ([ClinicalTrials.gov](ClinicalTrials.gov)) (<https://clinicaltrials.gov/>)\].

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Materials      NCT number   Cargo                                                             Center frequency   Therapeutic area
  -------------- ------------ ----------------------------------------------------------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Microbubbles   NCT\         Monoclonal antibodies in combination with chemotherapy            Not Provided       Colorectal Cancer, Hepatic Metastases
                 03458975                                                                                          

  Microbubbles   NCT\         Perflutren Protein-Type A Microspheres                            Not Provided       Hepatocellular Carcinoma, Liver Cancer
                 03199274                                                                                          

  Microbubbles   NCT\         platinum and gemcitabine                                          1.9 MHz            Gastrointestinal Neoplasms
                 02233205                                                                                          

  Microbubbles   NCT\         Gemzar                                                            1.9 MHz            Pancreatic Adenocarcinoma
                 01674556                                                                                          

  Microbubbles   NCT\         Recombinant tissue plasminogen activator                          Not Provided       Cerebrovascular Stroke
                 01678495                                                                                          

  Liposomes      NCT\         Lyso-thermosensitive liposomal doxorubicin and Cyclophosphamide   Not Provided       Metastatic Breast Cancer, Breast Cancer Breast, Neoplasms, Stage IV Breast Cancer, Metastatic Cancer, Invasive Ductal Carcinoma of Female Breast, Invasive Ductal Breast Cancer, Adenocarcinoma Breast
                 03749850                                                                                          

  Liposomes      NCT\         Lyso-thermosensitive liposomal doxorubicin                        Not Provided       Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
                 02536183                                                                                          

  Liposomes      NCT\         Lyso-thermosensitive liposomal (LTSL) doxorubicin                 0.96 MHz           Liver Tumor
                 02181075                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Along with the rapid development of nanomaterials, nanoscale bubbles, droplets, micelles and nanoliposomes have been developed as novel nanomaterials in ultrasound-responsive drug-delivery systems ([@B115]; [@B1]). Some liposomes have been applied for drug delivery under ultrasound in clinical trials ([**Table 1**](#T1){ref-type="table"}).

Herein, we will introduce several of the major nanoscale ultrasound-responsive materials used in drug/gene delivery. Furthermore, we will discuss the challenges and the development of ultrasound-responsive materials in drug/gene delivery.

Novel Ultrasound-Responsive Materials {#s2}
=====================================

Nanobubbles {#s2_1}
-----------

Nanobubbles are a type of nanoscale bubbles (1--1,000 nm) with gaseous cores and outer shells. As a ultrasound-responsive material, nanobubbles were designed originally as contrast agents to enhance ultrasound imaging, and developed as drug-delivery carriers later ([@B13]).

In tumor tissues, the endothelial gaps range from 380 nm to 780 nm ([@B33]). Microbubbles with the size of 1--10 μm cannot generally extravasate from blood vessels to tumor tissues. However, "leaky" tumor vessels and obstructive lymphatic drainage make nanobubbles with the size of 10--780 nm extravasate through endothelial gaps and accumulate in tumor tissue *via* the EPR effect ([@B27]). Therefore, nanobubbles show great potential in drug/gene delivery for the diagnosis and therapy of cancer because they can accumulate in tumor tissues and interact with tumor cells directly. Upon ultrasound sonication, nanobubble-induced sonoporation on cells can also enhance the efficiency of drug/gene delivery ([@B128]). As early as 2009, [@B121] used ultrasound-responsive nanobubbles to control the delivery of gene to skeletal muscle both in BALB/c mice. This is the first report to use isotopic imaging (PET or SPECT) to realize visualization of gene transfection and to provide an easy way to detect the transfection of gene in clinic especially in vascular diseases and muscular dystrophy. [@B123] used poly(lactide-co-glycolic acid) (PLGA) as the shell and octafluoropropane (C~3~F~8~) gas as core of nanobubbles to load paclitaxel, and further modified them with A10-3.2 aptamer to target prostate cell-specific membrane antigen (PSMA) for therapy of prostate cancer. Under low-frequency ultrasound stimuli, the nanobubble (PTX-A10-3.2-PLGA NB) achieved high drug release that induced significant apoptosis *in vitro* and significant inhibition of growth of tumor cells in BALB/c nude mice with xenograft tumors, and provided biological imaging of prostate-cancer cells. Subsequently in 2018, this research team synthesized cationic nanobubbles (CNBs) with same gas core decorated with A10-3.2 aptamer (siFoxM1-Apt-CNBs) for anti-tumor-targeted delivery of siRNA-FoxM1(Forkhead box M1) ([@B125]). The transfection efficiency of siRNA was improved significantly, whereas FoxM1 expression was reduced significantly after siFoxM1-Apt-CNBs combined with ultrasound stimuli in xenograft tumors in nude mice as well as in PSMA-positive LNCaP cells *in vivo*. These actions led to significant inhibition of tumor growth and prolonged mice survival.

[@B10] used C~3~F~8~ gas as the core and phospholipids as shells to prepare nanobubbles for delivering isocitrate dehydrogenase 1 (IDH1)-siRNA to gliomas. The siRNA-loaded nanobubbles interfered significantly expression of IDH1 *in vitro* and *in vivo* under ultrasound sonication. [@B94] modified ultrasound-mediated resveratrol-embedded nanobubbles containing C~3~F~8~ core with anti-N-cadherin 2 antibody (which is regarded as a specific binding ligand of nucleus pulposus cells in intervertebral disks) to increase the drug concentration in intervertebral disks for slowing down their degeneration *in vivo*. [@B103] developed low-frequency ultrasound-responsive nanobubbles composed of C~3~F~8~ core and PEGylated lipid shell to deliver a plasmid, the expression vector of brain-derived neurotrophic factor (BDNF) for treating acute injury to the spinal cord, and microtubule-associated protein 2 (MAP-2) antibody to modify the nanobubbles to enhance the targeting. They found that combined treatment of ultrasound and nanobubbles increased BDNF expression significantly *in vitro* and *in vivo*, and improved recovery of spinal-cord injury, indicating that nanobubbles are potential ultrasound-responsive materials in drug/gene delivery. Some other studies are enumerated in [**Table 2**](#T2){ref-type="table"}.

###### 

Summaries of the studies on ultrasound-responsive nanobubbles.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Core                               Shell                                              Cargo                                                    Ultrasonic frequency   Therapeutic area                                             Study
  ---------------------------------- -------------------------------------------------- -------------------------------------------------------- ---------------------- ------------------------------------------------------------ -----------
  Gas-generating calcium carbonate   PEG-PAsp                                           Doxorubicin                                              40 MHz                 Squamous Cell Carcinoma                                      ([@B80])

  C~3~F~8~                           Herceptin-\                                        No cargo                                                 5--12 MHz              Her-2-positive Breast Cancers                                ([@B46])
                                     PEGylated phospholipid-shell                                                                                                                                                                    

  CF~4~                              PLGA                                               Doxorubicin                                              1 MHz                  VX2 Liver Tumor                                              ([@B77])

  C~3~F~8~                           Herceptin-PEG-PLGA                                 Paclitaxel                                               1 MHz\                 Breast Cancer                                                ([@B101])
                                                                                                                                                 and\                                                                                
                                                                                                                                                 40 MHz                                                                              

  C~5~F~12~                          Glycine/PEG/RGD-\                                  Doxorubicin                                              Not Provided           Liver Tumor                                                  ([@B64])
                                     modiﬁed poly(methacrylic acid)                                                                                                                                                                  

  Oxygen                             Sodium carboxymethylcellulose                      Mitomycin-C                                              40 MHz                 Bladder Cancer                                               ([@B9])

  C~3~F~8~\                          DPPC, DSPE-PEG2k and DPPA                          Doxorubicin                                              7 MHz                  Tongue Squamous Carcinoma                                    ([@B14])
  +\                                                                                                                                                                                                                                 
  UCNP--CN                                                                                                                                                                                                                           

  C~3~F~8~                           Mix of DPPC and DPPA                               pc DNA3.1(+)/PNP plasmid                                 1.3 MHz                Hepatocellular Carcinoma                                     ([@B136])

  C~3~F~8~                           Folate-conjugated N-palmitoyl chitosan             No cargo                                                 7 MHz                  Oral Epidermoid Cancer Cells, Cervical Cancer, Lung Cancer   ([@B95])

  C~3~F~8~                           Mix DSPC, DSPE-PEG2000 and DSPE-PEG2000-biotin     Apatinib                                                 1 MHz                  Liver Tumor                                                  ([@B112])

  C~5~H~2~F~10~                      Polymer shell composing of chitosan and lecithin   Paclitaxel and survivin inhibitor sepantronium bromide   3 MHz                  Lung Cancer                                                  ([@B8])

  C~3~F~8~                           PLA-PEG-NH~2~                                      No cargo                                                 9.0 MHz                Breast Cancer                                                ([@B93])

  1% CO~2~                           Protein                                            The pEGFP and pCMV-Luc reporter plasmids                 18 MHz                 Breast Cancer                                                ([@B110])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Droplets {#s2_2}
--------

Droplets are especially ultrasound-responsive liquid nanomaterials consisting of volatile perfluorocarbons (PFCs). It can undergo a phase transition through ultrasound-induced acoustic droplet vaporization or heat. After ultrasound stimulation, droplets can expand and convert into nanobubbles. This characteristic feature improves the ultrasonic contrast and triggers the release of loading agents specifically. Moreover droplets are more stable than gas bubbles in blood circulation at 37°C because droplets maintain their liquid core in the circulation avoiding gas dissolution ([@B56]; [@B59]). Stable PFC emulsions, commonly used droplets, can be prepared to \~200 nm in diameter ([@B25]), which is beneficial for circulating for a longer time *in vivo*, passing into tissues or cells, and enhancing the EPR effect ([@B97]). More interestingly, [@B58] supposed that the disruption of droplets may break down the membrane of endosome to aid the escape from the endosome endocytosis pathway of macromolecules such as genes. Their findings provide a new strategy for delivering therapeutic agents especially large molecules like genes upon ultrasound sonication.

Droplets, in general, are used to load lipophilic drugs, such as 10-hydroxycamptothecin (HCPT). HCPT is an efficacious anticancer drug but has limited clinical application due to its poor hydrophilicity. Encapsulation of lipophilic materials could improve the therapeutic efficacy of HCPT against cancer ([@B135]; [@B63]; [@B130]; [@B66]; [@B67]). Based on this information, [@B69] prepared an ultrasound-responsive droplet consisting of four parts: folic acid (FA) for overexpression of FA receptors on cancer cell membranes; superparamagnetic Fe~3~O~4~ for imaging; HCPT for cancer treatment; a PFC as the droplet core. The PFC core could undergo droplet vaporization upon sonication to cause HCPT release and enhance ultrasound imaging.

[@B90] developed a novel nanoemulsion containing a perfluoro-15-crown-5-ether (PFCE) core with good stability and reversible transition from droplet to bubble. Moreover, the novel nanoemulsions could realize ultrasound and ^19^Flourine magnetic resonance dual-mode imaging, and enhance the inhibitory efficiency of paclitaxel-loaded nanoemulsions on the growth and metastasis of breast and pancreatic cancer cells in mice.

Doplets were also investigated in the application of brain diseases. [@B16] compared the safety of microbubbles and droplets for drug delivery to the brain under focused ultrasound. In their studies, the same lipid compositions were used as the outer shells of microbubbles and droplets: perfluorobutane as the microbubble core and PFC as the droplet core. The cavitation induced by droplets required a higher threshold and droplets could deliver the drug more safely and more effectively than microbubbles in the brain. In 2018, another study on the delivery of biomolecules into the brain using droplets was published by colleagues in the team ([@B125]). These findings demonstrated that ultrasound droplet-mediated delivery was a novel approach to deliver drug/gene into the brain effectively. Other up-to-date researches are listed in [**Table 3**](#T3){ref-type="table"}.

###### 

Summaries of the studies on ultrasound-responsive droplets.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Core        Shell                                                       Cargo                                  Ultrasonic frequency       Therapeutic area                     Study
  ----------- ----------------------------------------------------------- -------------------------------------- -------------------------- ------------------------------------ -----------
  C~6~F~14~   Alginate                                                    Doxorubicin\                           28 k Hz\                   Multidrug Resistant Ovarian Cancer   ([@B7])
                                                                          and\                                   and\                                                            
                                                                          curcumin                               1 MHz                                                           

  C~5~F~12~   PLGA                                                        Cetuximab and 10-Hydroxycamptothecin   1 MHz                      Anaplastic Thyroid Carcinoma         ([@B119])

  C~9~F~20~   Mix of DSPC and mPEG-DSPE                                   Lidocaine                              2.25 MHz                   Acute and Chronic Pain               ([@B104])

  C~5~F~12~   Perylene diimide                                            ZnF~16~Pc                              40 MHz                     Malignant Glioblastoma               ([@B108])

  C~6~F~14~   Phosphatidyl ethanolamine                                   Ce6                                    1 MHz                      Breast Cancer                        ([@B132])

  C~3~F~8~    Mix of DSPE-PEG3400-t Ly P-1, DPPG, DPPC, and cholesterol   10-Hydroxycamptothecin                 1 MHz                      Breast Cancer                        ([@B139])

  C~5~F~12~   Mix of POPC, POPE, cholesterol, and DSPE-PEG-2000           Camptothecin                           2 MHz                      Melanoma                             ([@B32])

  C~5~F~12~   Mix of DPPC, DSPE-\                                         IR780                                  650 k Hz for treatment,\   Breast Cancer                        ([@B138])
              m PEG2000, cholesterol                                                                             12 MHz for imaging                                              

  C~6~F~14~   O-carboxymethyl chitosan                                    Doxorubicin                            9.0 MHz                    Prostatic Cancer                     ([@B78])

  C~7~F~16~   Pluronic F68                                                Basic ﬁbroblast growth factor          2.5 MHz                    Ischemic Cardiovascular Diseases     ([@B20])

  C~6~F~14~   Polydopamine                                                No cargo                               7.5 MHz                    Breast Cancer                        ([@B73])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Micelles {#s2_3}
--------

Micelles are, in general, generated through self-assembly of polymers containing a hydrophilic group and a hydrophobic alkane ([@B42]). Moreover, the diameters of micelles, which range from 10 nm to 100 nm, will help their application in nanoformulations ([@B40]; [@B127]). Amphiphilic structures enable hydrophilic drugs and hydrophobic drugs to be encapsulated readily in micelles. The moderate thermal effect induced by ultrasound can increase the cell membrane penetrability resulting in enhancing extravasation in targeted cells ([@B91]). And increasing evidence has shown that micelles can be destroyed under shockwaves produced by ultrasound to release cargo loaded in micelles and deliver them to target tissues ([@B1]). Ultrasound-responsive micelles not only achieve the control of space release but also the quantity of release, since they can reassemble again when the ultrasound shuts off ([@B41]; [@B107]). Hence, micelles are also potential materials for ultrasound-responsive delivery.

As early as in 2006, [@B15] prepared micelles composed of three kinds of pluronics, F127, L61 and P85 as gene-delivery carriers under sonication. They found that, upon sonication, these three types of micelles enhanced the efficiency of gene transfection in 3T3-MDEI, C2C12, and CHO cell lines. Later, [@B124] developed a mixed micelle of pluronic P123/F127 polymers to encapsulate curcumin. They showed that curcumin was released at specific sites under ultrasound sonication, and that sonication increased cellular uptake of curcumin compared with that using free curcumin. *In vitro*, curcumin released from micelles increased along with increasing ultrasound intensity. Furthermore, curcumin-loaded micelles decreased the tumor weight by \~6.5-fold upon ultrasound sonication compared with the group without sonication exposure. [@B48] studied doxorubicin (DOX) release with the help of high-intensity focused ultrasound (HIFU). The center frequency of the pre-clinical HIFU system they used was 1.5 MHz. Under high-intensity focused ultrasound, the structure of micelles loaded with DOX and hydrophobic 1,3-bis-(2,4,6-trimethylpheny l) imidazolylidene nitric oxide (IMesNO, a donor of nitric oxide, NO) was destroyed, and IMesNO was released from the micelles to produce NO. In cancer tissues, NO improved the EPR effect by expanding cancer blood vessels to increase blood blow, and subsequently enhanced the anticancer effect of DOX.

Nanoliposomes {#s2_4}
-------------

Liposomes show excellent biocompatibility because they consist primarily of lipid bilayers ([@B92]). Liposomes can often load hydrophilic molecules and lipophilic molecules to improve their pharmacokinetics and reduce systemic toxicity ([@B114]; [@B3]). Recently, accelerating evidence shows that nanoliposomes can deliver and release drugs/genes in target tissues upon ultrasound sonication ([@B21]; [@B72]; [@B105]; [@B70]). In general, nanoliposomes do not contain gas, so they are not particularly responsive to ultrasound. To achieve a particular response to ultrasound, nanoliposomes can be designed to contain vapor-phase molecules or encapsulated emulsions that can vaporize under ultrasound ([@B38]; [@B28]). When being exposed to ultrasound, cavitation or thermal effects can increase the release of drug/gene-loaded in nanoliposomes. Usually under sonication at high frequency, thermal effect takes the main role of delivery process. While under low frequency, cavitation plays an important role ([@B36]; [@B52]; [@B100]; [@B57]).

To improve the targeting ability of ultrasound-responsive nanoliposomes, [@B83] used an AG73 peptide targeting syndecan (which is highly expressed in neovascular vessels) to modify liposomes with a perfluoropropane core. This AG73 peptide-modification endowed liposomes with a perfluoropropane core to have good targeting ability to tumor cells and deliver plasmids to them effectively. In 2018, a new liposome-encapsulating gas, phosphorodiamidate morpholino oligomer, was used to induce antisense oligonucleotide-mediated "exon skipping" for treating Duchenne muscular dystrophy ([@B84]). This new liposome could deliver the antisense oligonucleotide to diseased muscles and release it upon ultrasound sonication.

Nowadays, a mixture of liposomes and microbubbles termed a "liposome--microbubble complex" (LMC) has been reported. The LMC has the high drug-loading ability of liposomes and ultrasound-responsive property of microbubbles. [@B137] fabricated a LMC as a drug vehicle to deliver paclitaxel. To overcome the disadvantage that LMC was effective *in vitro* but not *in vivo*, they used iRGD peptide, a nine-unit cyclic tumor-homing and tissue-penetrating peptide, to modify the LMC to achieve better permeability into blood vessels and tissues in a tumor-speciﬁc manner. This modified LMC showed higher toxicity to 4T1 breast cancer cells and antitumor efficacy in a subcutaneous tumor model.

Challenges {#s3}
==========

Ultrasound-responsive material-based drug/gene delivery has been explored widely in treating cancer ([@B50]; [@B89]; [@B26]; [@B134]; [@B47]), cardiovascular diseases ([@B35]; [@B19]; [@B11]), orthopedic diseases ([@B60]; [@B88]; [@B54]), ocular diseases ([@B5]; [@B116]; [@B117]; [@B55]) and brain diseases ([@B113]; [@B102]), and also applied in vaccine immunization ([@B106]; [@B24]). However, application of ultrasound-responsive materials in drug/gene delivery faces certain challenges.

First, the prerequisite for treating diseases is a sufficient amount of drug/gene delivered and released in diseased tissues. Most ultrasound-responsive materials need an ultrasound-responsive core (gaseous, PFC, or gas-generating). These ultrasound-responsive cores consume a lot of space in ultrasound-responsive materials (microbubbles, nanobubbles, or droplets), which makes lower drug/gene-loaded contents, and decrease the amount of drug/gene delivered to diseased tissues, and eventually lead to limited therapeutic efficacy ([@B51]; [@B25]; [@B96]). Second, nanoscale ultrasound-responsive materials have advantages over microbubbles with regard to targeted delivery of drugs and genes, but these nanomaterials are less responsive than microbubbles ([@B99]). So nanomaterials require higher ultrasound intensity to induce cavitation for effective release of drugs/genes from nanomaterials. But ultrasound of high intensity can cause damage to neighboring healthy tissues. High-intensity ultrasound also induces the rapid collapse of bubbles and rapid release of the drug/gene loaded in the bubbles, which may not meet the need for sustained release of some drugs (e.g., insulin).

The last but not the least, ultrasonic parameters are still noticeable issues. Low- and high-frequency ultrasound can damage biologic tissues when sonication-induced heating is too high, and the pore formation on cell membranes is irreversible ([@B76]). Therefore, the intensity and duration of ultrasound sonication must be controlled. [@B53] found that pulsed-focused ultrasound induced the opening of the blood--brain barrier and was accompanied by increased expression of heat-shock protein 70, interleukin-1, interleukin-18, tumor necrosis factor-α, and inflammation of brain tissues, suggesting that application of ultrasound-responsive materials in drug/gene delivery to the brain system should be done with extreme caution.

Conclusions {#s4}
===========

Ultrasound-responsive materials can deliver drugs/genes to targeted tissues, and induce the release of drugs/genes in specific sites upon ultrasound sonication. However, most evidence has arisen from *in vitro* and *in vivo* animal experiments. Few clinical trials have investigated the role of ultrasound-responsive materials in drug/gene delivery. Thus, more clinical trials should be conducted to confirm the outlook of ultrasound-responsive materials in drug/gene delivery.

Recent studies have revealed that the major reason limiting application of ultrasound-responsive materials is their low drug/gene-loaded content. Enhancing the drug/gene-loaded content in ultrasound-responsive materials will be a "hotspot" for clinical translation of ultrasound-responsive materials.

In addition, sonoporation is regarded to be the main reason that ultrasound-responsive materials enhance the release of loaded drugs/genes. However, the interaction of ultrasound and ultrasound-responsive materials is complicated, and can induce mechanical forces, sonoporation, heating, and sonochemical effects. Therefore, better understanding of how ultrasound-responsive materials enhance release of loaded drugs/genes will lay a solid foundation to boost development of ultrasound-responsive materials in drug/gene delivery.
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